Storia in 2 fonti

Greg Verdine’s LifeMine raises $263M for safer immunosuppressant

LifeMine Therapeutics raises $263M across Series D and E rounds to advance LIFE-001, a fungal-derived calcineurin inhibitor for transplant patients.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo5 g fa

Greg Verdine’s LifeMine raises $263M for safer immunosuppressant

LifeMine Therapeutics raises $263M across Series D and E rounds to advance LIFE-001, a fungal-derived calcineurin inhibitor for transplant patients.

originale

biopharmadive.com6 g fa

With $263M, LifeMine unearths a new drug for organ transplants

Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.

Leggi questa versione → originale

Timeline cronologica

giovedì 6 agosto 2026·biopharmadive.com
With $263M, LifeMine unearths a new drug for organ transplants
Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting…
giovedì 6 agosto 2026·endpoints.news
Greg Verdine’s LifeMine raises $263M for safer immunosuppressant
LifeMine Therapeutics raises $263M across Series D and E rounds to advance LIFE-001, a fungal-derived calcineurin inhibitor for transplant patients.